Truist Securities Maintains Buy on NovoCure, Lowers Price Target to $105
Truist Securities analyst Gregory Fraser maintains NovoCure (NASDAQ:NVCR) with a Buy and lowers the price target from $118 to $105.
Daily Biotech Pulse: GSK’s Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion’s Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Recap of Tuesday’s Biotech Catalysts – End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Ionis shares are trading low 4 percent at $35.10 in the after-hours session
Novocure Enrolls First Patient In KEYNOTE-B36, A Pilot Study Of Tumor Treating Fields Together With KEYTRUDA For Patients With First-Line Stage III Non-Small Cell Lung Cancer
Novocure (NASDAQ:NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA. KEYNOTE-B36
The Daily Biotech Pulse: Setback For NRx Pharma’s COVID Study, Fast Track Tag For Pfizer’s NASH Combo Therapy, Reata’s Ataxia Drug In FDA Review
Here's a roundup of top developments in the biotech space over the last 24 hours:
HC Wainwright & Co. Initiates Coverage On NovoCure with Buy Rating, Announces Price Target of $115
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on NovoCure (NASDAQ:NVCR) with a Buy rating and announces Price Target of $115.
Piper Sandler Maintains Overweight on NovoCure, Lowers Price Target to $100
Piper Sandler analyst Jason Bednar maintains NovoCure (NASDAQ:NVCR) with a Overweight and lowers the price target from $125 to $100.
NovoCure: Q1 Earnings Insights
NovoCure (NASDAQ:NVCR) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM.
Here's what investors need to know about the announcement.
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours:
Novocure’s TTFields Show Improved Progression-Free, Overall Survival Over Matched-Control
Novocure Ltd (NASDAQ: NVCR)